BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21810517)

  • 1. Predictive molecular classifiers in colorectal cancer.
    Bohanes P; LaBonte MJ; Winder T; Lenz HJ
    Semin Oncol; 2011 Aug; 38(4):576-87. PubMed ID: 21810517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of molecular biomarkers in individualized treatment of colorectal cancer.
    De Mattos-Arruda L; Dienstmann R; Tabernero J
    Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
    Yarom N; Jonker DJ
    Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine.
    Shi C; Washington K
    Am J Clin Pathol; 2012 Jun; 137(6):847-59. PubMed ID: 22586043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular markers in the treatment of metastatic colorectal cancer.
    Wilson PM; Labonte MJ; Lenz HJ
    Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
    Prenen H; Tejpar S; Van Cutsem E
    Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
    Dempke WC; Heinemann V
    Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive molecular markers in colorectal carcinoma.
    Bendardaf R; Lamlum H; Pyrhönen S
    Anticancer Res; 2004; 24(4):2519-30. PubMed ID: 15330208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the molecular diagnosis and prognosis of colorectal cancer.
    Huerta S
    Expert Rev Mol Diagn; 2008 May; 8(3):277-88. PubMed ID: 18598107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of biomarkers in colorectal cancer.
    Newton KF; Newman W; Hill J
    Colorectal Dis; 2012 Jan; 14(1):3-17. PubMed ID: 21040359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics and -genetics in colorectal cancer.
    Pohl A; Lurje G; Manegold PC; Lenz HJ
    Adv Drug Deliv Rev; 2009 May; 61(5):375-80. PubMed ID: 19100300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.
    Zwierzina H; Bardelli A; Ciardiello F; Gariboldi M; HĂ„kansson L; Lambrechts D; Lind GE; Loeffler-Ragg J; Schmoll H; Siena S; Tabernero J; Van Cutsem E
    Curr Opin Mol Ther; 2010 Dec; 12(6):703-11. PubMed ID: 21154162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data.
    Mountzios G; Dimopoulos MA; Soria JC; Sanoudou D; Papadimitriou CA
    Crit Rev Oncol Hematol; 2010 Aug; 75(2):94-109. PubMed ID: 19914087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Omics docking and molecular classification in colorectal cancer].
    Peng Y; Shen S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Nov; 35(11):1201-6. PubMed ID: 21131745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of tumor markers and biomarkers in colorectal cancer.
    Lech G; Slotwinski R; Krasnodebski IW
    Neoplasma; 2014; 61(1):1-8. PubMed ID: 24195503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies.
    Oikonomou E; Pintzas A
    Anticancer Res; 2006; 26(2A):1077-84. PubMed ID: 16619509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
    Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
    J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.